Public health impact and cost-effectiveness of implementing gender-neutral vaccination with a 9-valent HPV vaccine in Japan: a modeling study
Including boys and men in Japan's HPV vaccination strategy is predicted to provide additional public health benefits compared to FOV and to be cost effective, particularly while the female VCR remains low and if the full vaccine series is completed before age 15.
Authors
- Cody Palmer (ORCID: https://orcid.org/0000-0002-9060-5999)
- Xuedan You (ORCID: https://orcid.org/0000-0002-2551-9111)
- Keisuke Tobe (ORCID: https://orcid.org/0000-0003-2761-4531)
- Ya-Ting Chen
- Taizo Matsuki (ORCID: https://orcid.org/0000-0002-0591-4261)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck Biopharma Co., Ltd. (Japan) (JP)
- Decision Sciences (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1080/13696998.2025.2520703
- Citations
- 2
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- University of South Alabama
- Merck Sharp and Dohme